Myocardial Infarction News and Research

RSS

miRagen and t2cure enter licensing agreement for microRNA 92 technology

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and t2cure, a clinical stage biopharmaceutical company developing progenitor cell-based regenerative therapeutics for cardiac or peripheral vascular diseases, announced today that they have entered into a licensing agreement

30 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Phase 3 study of VEGF Trap-Eye regimen meets primary endpoint in patients with wet AMD

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare announced that in two parallel Phase 3 studies in patients with the neovascular form of age-related macular degeneration (wet AMD), all regimens of VEGF Trap-Eye (aflibercept ophthalmic solution), including VEGF Trap-Eye dosed every two months, successfully met the primary endpoint compared to the current standard of care, ranibizumab dosed every month.

22 Nov 2010

Study highlights poor outcomes for patients with ESRD admitted over weekend

Patients with end-stage renal disease who are admitted to the hospital during the weekend are at increased risk of death, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

Community education shortens onset to hospital arrival times for patients with chest pain

Systematic education in rural and suburban communities can significantly shorten onset to hospital arrival times for patients with chest pain, according to study findings to be presented Nov. 16 at the 2010 annual American Heart Association (AHA) Scientific Sessions in Chicago.

18 Nov 2010

Study finds sfrp2 protein may play a role in accelerating heart muscle repair

Heart tissue and stem cells spring into action to begin repairing muscle damaged in a heart attack, and researchers at Duke University School of Medicine found that a protein naturally produced in the body may potentially play a role in accelerating heart muscle repair.

18 Nov 2010

Researchers report results from Phase III DEFINE study for coronary heart disease

Researchers today presented results from the Phase III DEFINE (Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib) study with Merck's investigational CETP inhibitor, anacetrapib. In the trial of 1,623 patients with coronary heart disease (CHD) or CHD risk equivalents, anacetrapib showed no significant differences from placebo in the primary safety measures studied.

18 Nov 2010

Fat-derived stem cells can boost heart function following acute attack

Fat cells liposuctioned from a patient's belly can safely boost heart function after a heart attack, according to a first-of-its-kind study presented at the American Heart Association's Scientific Sessions 2010.

17 Nov 2010

New stem cell-infused patch improves heart function after myocardial infarction

University of Cincinnati (UC) researchers have found that applying a stem cell-infused patch together with overexpression of a specific cell instruction molecule promoted cell migration to damaged cardiac tissue following heart attack and resulted in improved function in animal models.

16 Nov 2010

Iron in plaque may predict risk of myocardial infarction

Plaque in a heart artery looks threatening, but cardiologists know that many of these buildups will not erupt, dislodge and block a vessel, causing a heart attack that can be fatal. Some will, however, and the challenge is to figure out atherosclerotic plaque that is dangerous and treat or remove it.

16 Nov 2010

Spectrum Pharmaceuticals to present ZEVALIN data at ASH Meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced a total of 11 ZEVALIN related data presentations (five oral, six posters) at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

15 Nov 2010

AHA/ASA announce need for comprehensive hospital certification program for heart and stroke care

The American Heart Association should develop a comprehensive hospital certification program with policies and evidence-based criteria for cardiovascular disease and stroke care in the United States, according to an American Heart Association Presidential Advisory published in Circulation: Journal of the American Heart Association.

15 Nov 2010

TCA Cellular Therapy receives QTDP grant for adult stem cell therapies

TCA Cellular Therapy was recently awarded a Qualifying Therapeutic Discovery Program (QTDP) grant from U.S. Department of Health and Human Services. The program was highly competitive with nearly seven thousand applicants vying for funding.

14 Nov 2010

Research roundup: Doctors' industry ties; Patient safety and residents' hours; Designing a medical home

Archives of Internal Medicine: Physician Professionalism And Changes in Physician-Industry Relationships From 2004 to 2009 -"During the last 6 years a number of efforts have aimed to reduce, and in some cases eliminate, certain types of physician-industry relationships (PIRs)," including policies "that forbid physicians from accepting samples and receiving food and beverages in offices, limiting company representatives' access to physicians' offices and clinical areas, and banning faculty participation in speaker bureaus and other forms of promotional activity," write the authors.

12 Nov 2010

Study: Cognitive symptoms of depression cannot be discarded as risk factors for heart disease progression

Cognitive symptoms of depression cannot be simply discarded as risk factors for heart disease progression. When using a structured diagnostic interview, both somatic and cognitive symptoms of depression are associated with adverse cardiac outcome after adjusting for potential confounders.

11 Nov 2010

Hospitals need to work more to prevent heart attack deaths: Study

Door-to-balloon time has dropped dramatically as hospitals rush heart attack patients into treatment, but a five-year study released Monday shows quicker hospital care has not saved more lives.

10 Nov 2010

Angiotech reports $59.0 million total revenue for third quarter 2010

Angiotech Pharmaceuticals, Inc. today announced that it had released its financial results for the third quarter ended September 30, 2010.

9 Nov 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010